Nouvelle déclaration d'incident
No de la demande: 2012-1804
Numéro de référence du titulaire d'homologation: PROSAR Case 1 29860421
Nom du titulaire (nom légal complet, aucune abbréviation): Syngenta Canada Inc.
Adresse: 140 Research Lane, Research Park
Ville: Guelph
État: Ontario
Pays: Canada
Code postal /Zip: N1G4Z3
Incident chez l'humain
Pays: UNITED STATES
État: NORTH CAROLINA
ARLA No d'homologation ARLA No de la demande d'homologation EPA No d'homologation. Inconnu
Nom du produit: Gramoxone (non-specific)
Liquide
Oui
Inconnu
Site: Agricultural-Outdoor/Agricole-extérieur
Specify Type: Unknown
Inconnu
Autre
Sexe: Homme
Âge: >19 <=64 yrs / >19 <=64 ans
Système
Unknown / Inconnu
Oui
Oui
Inconnu
Professionnel
Contact avec la zone traitée
Quelle était l'activité? Patient walked through the treated field wearing canvas shoes; did not wash off after got product on skin.
Aucun
Peau
Unknown / Inconnu
>24 hrs <=3 days / >24 h <=3 jours
Case 1-29860421 Human 1-HS0YE: The reporter, a family member, notified the registrant on 04/21/12 of her fathers exposure to an herbicide containing the active ingredient Paraquat. According to the reporter, her father had sprayed the product about one week prior to the call. He had applied the product at a dilution of 6 ounces to one gallon of water. At some unspecified time after application, the patient had then walked through the field wearing some canvas shoes. He did not wash off after he got the product on his skin. On 04/16/12 the patient developed some difficulty walking (legs buckling) and by the time of the call was exhibiting some slurred speech. The reporter stated that the patient had been to the hospital where blood work had been run; no definitive diagnosis had been established though a stroke was on the list of rule-outs. The patients sense of muscle weakness persisted (could not hold himself up). The patients skin had not been damaged by dermal contact with the herbicide. During the 04/21/12 call it was discussed that the patients symptoms were inconsistent with a dermal exposure to the product. Systemic toxicity to the product would be expected to manifest with damage to the lungs, kidneys and liver. Neurologic signs would not be expected unless the patients liver values were markedly abnormal on blood work. A recommendation was made to continue working with the doctors to identify an underlying cause for the patients symptoms. A follow-up call to the reporter on 04/28/12 revealed that the patient was at home again and was doing fine. He had been diagnosed as having suffered a light stroke. The physicians on the case did not believe the patients symptoms were related to the product.
Majeure